Dr Lal PathLabs plans to acquire 70% stake in SN Genelab for around Rs 168 crore
The Economic Times reports the deal includes a potential Rs 31.5 crore earn-out tied to performance and is expected to close by November 30, 2026.
TLDR
The Economic Times reports that Dr Lal PathLabs plans to acquire a 70% stake in SN Genelab for around Rs 168 crore. The deal includes a potential performance-linked earn-out of Rs 31.5 crore, with closing expected by November 30, 2026. The report says SN Genelab would become a subsidiary, expanding Dr Lal PathLabs’ genomics and diagnostic capabilities.
Dr Lal PathLabs plans to acquire 70% stake in SN Genelab for around Rs 168 crore
The Economic Times reports the deal includes a potential Rs 31.5 crore earn-out tied to performance and is expected to close by November 30, 2026.
TLDR
The Economic Times reports that Dr Lal PathLabs plans to acquire a 70% stake in SN Genelab for around Rs 168 crore. The deal includes a potential performance-linked earn-out of Rs 31.5 crore, with closing expected by November 30, 2026. The report says SN Genelab would become a subsidiary, expanding Dr Lal PathLabs’ genomics and diagnostic capabilities.